CSL LIMITED
- Country
- π¦πΊAustralia
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.csl.com.au/
Clinical Trials
32
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)β’ Click on a phase to view related trials
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 30
- Registration Number
- NCT01632852
- Locations
- πΊπΈ
Robert H. Lurie Comprehensive Cancer Center of Northwestern University Medical School, Chicago, Illinois, United States
πΊπΈSidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
πΊπΈWeill Cornell Medical College, New York, New York, United States
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients
- Conditions
- Stable Atherothrombotic Disease
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 45
- Registration Number
- NCT01499420
- Locations
- πΊπΈ
Study Site, Rapid City, South Dakota, United States
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01281774
- Locations
- π¦πΊ
Q-Pharm, Brisbane, Queensland, Australia
Safety, Tolerability and Pharmacokinetics of CSL112 in Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2010-05-25
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 57
- Registration Number
- NCT01129661
- Locations
- π¦πΊ
CMAX, Adelaide, South Australia, Australia
Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency
- Conditions
- Primary Immune Deficiency
- Interventions
- Drug: Immunoglobulin G (Ig NextGen 16%)
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- CSL Limited
- Target Recruit Count
- 41
- Registration Number
- NCT00680446
- Locations
- π¦πΊ
Campbelltown Hospital, Campbelltown, New South Wales, Australia
π¦πΊSydney Children's Hospital, Randwick, New South Wales, Australia
π¦πΊRoyal Adelaide Hospital, Adelaide, South Australia, Australia
- Prev
- 1
- 2
- Next